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Abstract. Lymphatic uptake of interstitially administered
agents occurs by passive convective–diffusive inflow
driven by interstitial concentration and pressure, while
the downstream lymphatic transport is facilitated by active
propulsive contractions of lymphatic vessel walls. Nearinfrared fluorescence imaging in mice was used to measure these central components of lymphatic transport for
the first time, using two different-sized molecules––methylene blue (MB) and fluorescence-labeled antibody immunoglobulin G (IgG)-IRDye 680RD. This work confirms the
hypothesis that lymphatic passive inflow and active propulsion rates can be separated based upon the relative
differences in Stokes–Einstein diffusion coefficient. This
coefficient specifically affects the passive-diffusive uptake
when the interstitial volume and pressure are constant.
Parameters such as mean time-to-peak signal, overall
fluorescence signal intensities, and number of active peristaltic pulses, were estimated from temporal imaging data.
While the mean time to attain peak signal representative
of diffusion-dominated flow in the lymph vessels was 0.6 
0.2 min for MB and 8  6 min for IgG, showing a size
dependence, the active propulsion rates were 3.4 
0.8 pulses∕ min and 3.3  0.5 pulses∕ min, respectively,
appearing size independent. The propulsion rates for both
dyes decreased with clearance from the interstitial injection-site, indicating intrinsic control of the smooth muscles
in response to interstitial pressure. This approach to sizecomparative agent flow imaging of lymphatic function can
enable noninvasive characterization of diseases related to
uptake and flow in lymph networks. © The Authors. Published by
SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution
or reproduction of this work in whole or in part requires full attribution of the
original publication, including its DOI. [DOI: 10.1117/1.JBO.21.10.100501]
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The lymphatic system provides the central channel for interstitial fluid flow, dissemination of immune cells, molecular
response to pathogens,1 cancers metastases,2 and potential for
drug delivery.3 This system functions without an internal pump
and net lymph flow has contributions from the rate of lymph
formation and solute uptake at the interstitium, and lymph propulsion. Lymph formation and solute uptake are predominantly
driven by convection and diffusion into the lymphatic capillaries
in the interstitial space;4 on the other hand, skeletal muscle
movements, blood pressure, and phasic smooth muscle contractions of the collector lymph vessels induce the pressure for
propelling lymph along the vessel length.5 Interstitial administration of imaging tracers6 has implications in a range of disease
conditions, such as metastatic cancers of the skin, breast, abdomen, and head for diagnostic staging.7 Yet, while this imaging is
critically important for the majority of surgical oncology procedures, there have been few attempts to quantitatively visualize
and study the lymphatic system,8–10 and extract possible parametric values for assessment of function10 and disease status.11
Most studies have focused on relative observations of intensity,
yet there is good potential for making decisions based on quantitative parametric information derived from imaging lymph
nodes12 and lymphatic vessels.13 Herein, we hypothesized
that by imaging lymphatic flow of two different sized tracers,
the relative contributions of propulsive flow and the convective–diffusive interstitial solute uptake could be separated and
quantified.
Wide-field near-infrared fluorescence (NIRF) imaging and
intravital microscopy are two of the most common methods
applied in mechanistic studies of the lymphatics in vivo with
the former showing promise for imaging human subjects as
well as small animals,14 and the latter applied to finding
basic mechanisms. NIRF methods also offer the benefit of
high temporal resolution and simultaneous multiagent
imaging.15 However, drug and dye delivery via the lymphatics
suffers from issues of high heterogeneity, and intensity-based
metrics often need to be considered carefully with appropriate
correction for delivery differences.16 An understanding of tracer
lymphatic pharmacokinetics and the influencing factors is also
essential for designing appropriate imaging studies and protocols. For example, Aldrich et al.17 compared the effects of varying concentration of indocyanine green on the lymphatic
propulsion, and Wu et al.18 compared the uptake of albuminbound versusfree IRDye 680RD from mouse paw by axillary
nodes. Lymphatic flow in the vessels is driven by diffusion
and convection at the interstitium, and the lymphatic contractions of the smooth muscles lining the collector lymph vessels
induce the periodic pressure gradients to maintain lymph flow.
Valves present along each lymph vessel prevent retrograde flow,
and the rhythmic smooth muscle contractions propel lymph
from one lymph vessel segment (lymphangion) to the next.5
Bulk fluid flow at the interstitium into lymph capillaries is dominated by the pressure-driven flow induced by the injected fluid
volume, and the influx of tracer molecules is dominated by diffusion. The molecular size, shape, charge, and affinity to proteins in the lymph can each influence the transport of solute
molecules at the injection size into the lymphatics and,
hence, affect the overall tracer kinetics, yet the lymph formation
and propulsion processes are affected differently by these factors. The goal of this work was to quantitatively characterize the
lymphatic uptake and transport of a large nonspecific antibody
tracer [i.e., immunoglobulin G (IgG)], as compared to small
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dye molecules [i.e., methylene blue (MB)] approved for interstitial lymphatic administration,19 and extract parametric values
of the influence of molecule size upon the pharmacokinetics of
lymphatic transport. To the best of our knowledge, this is the
first quantitative study of active transport and passive uptake
mechanisms in the normal lymphatics for comparing large
and small tracers in the same animals.
Specifically, the difference in transport of MB (molecular
weight ∼300 Da), which may weakly and reversibly associate
with protein albumin (molecular weight ∼66.5 kDa) in the
lymph (association constant, K a ¼ 4.012 × 104 M−1 at 298 K20),
was analyzed and compared to the larger mouse IgG conjugated
to fluorophore (size >150 kDa). We defined the “active propulsion” component as the flow of fluorescence dye molecules
from one lymphangion to the next, i.e., peristalsis, as identified
by the number of contractions and relaxations of the lymph vessel. The overall transport of tracers through the lymphatics is a
combination of this active component and a passive diffusionand interstitial pressure-driven uptake component at the interstitium, which for simplicity is referred to as the “passive uptake.”
We documented the action of tracers in both the active and passive components of flow through the collector lymphatic
vessels4,5 when injection volume was fixed for both tracers,
thus eliminating any relative effects of pressure gradient in the
interstitium. The small size of MB, combined with its low affinity for albumin in lymph,21 makes its movement through the
lymphatic system very swift.
The antibody tracer used was mouse IgG (Athens Research
and Technology, Athens, Georgia) Isotype control antibody for
Erbitux labeled with IRDye 680RD (LI-COR Biosciences,
Lincoln, Nebraska). The labeling procedures for the former
are described in detail in previous work.7 The IgG-labeled solution was concentrated to μM concentrations. The MB (NDC
17478-504-10, Akorn Inc.) was diluted in phosphate-buffered
saline (PBS) to a concentration of ∼2.5 mM.
All animal experiments were carried out in accordance with
the Institutional Animal Care and Use Committee at Dartmouth
College under approved protocols. A total of 13, 8- to 10-weekold athymic nude female mice (Charles River, Wilmington,
Massachusetts) were used in this study. Animals were grouped
into two cohorts—MB-injected and mouse IgG-IRDye-injected.
All animals were maintained on a fluorescence-free diet for a
week prior to imaging. Prior to imaging, each animal was anaesthetized using 1.5% to 3% isofluorane (Piramal, Bethlehem,
Pennsylvania) in 1.5 L∕ min oxygen. It was then placed on
its side with the forelimb on one side of the body stretched
out so as to expose lymph nodes of the axilla, as shown in Fig. 1.
A preinjection image was captured to measure autofluorescence
background levels. The IgG-IRDye tracer was diluted in PBS so
that 10 μl contained 0.1 nmoles of protein. 10-μl volume of each
fluorescent tracer in PBS was injected intradermally using a 31gauge syringe needle into the base of a forepaw of each animal.
All fluorescence imaging was performed using a Pearl® Impulse
system (LI-COR Biosciences Inc., Lincoln, Nebraska), which
provides planar surface images in two near-infrared bands.22
The system was set up to acquire 700-nm channel images at
1 frame every 2 s for the first 10 to 20 min, and then at 2 frames
per minute. Imaging was performed for 120 min following
injection.
Image analysis was performed using MATLAB® (R2014b,
Mathworks, Natick, Massachusetts) and Image J Software
[1.47 v, National Institutes of Health (NIH)]. Regions of interest
Journal of Biomedical Optics

White light + fluorescence overlay (green)

Fig. 1 Uptake of MB from the injection site in the paw to an axillary
lymph node (white arrow).

(ROIs) were selected over the visible lymph node and its afferent
lymphatic vessel. For nodes, circular ROIs of 2020-μm diameter
were drawn, and for lymphatic vessels, three ROIs each ∼500 μm
in diameter were selected over different sections of the collector
lymphatics. Care was taken to place the ROIs over regions
where there was evidence of pumping function. We expected
to see sections with a lack of pumping function along each vessel; these regions were avoided for the purpose of this study.
Fluorescence signal at various time points after tracer administration was observed. Statistical analyses were performed using
Microsoft Excel, assuming equal variances across all groups.
A student’s t-test was used to identify parameters with significant differences between the MB and IgG cohorts.
Figure 1 shows the uptake of MB from an injection site in a
mouse paw to the axillary lymph node. The paw had to be
covered to block out the large fluorescence signal from the
deposited dye. The transport of tracer appeared to have both
an active pumping and a passive diffusion- and pressure-driven
component as expected.4 A sample set of measured MB uptake
curves in one mouse is shown in Fig. 2. The overall uptake
shapes were recovered using temporal smoothing with piecewise spline fitting with a smoothing resolution of 18 s, and
the dotted lines represent the previously defined “passive
uptake.” Based on the fluorescence intensity signal strength,
only one vessel segment was chosen for analysis in each animal.
This was generally the vessel segment close to the lymph node,
as signal-to-noise was poor at segments close to the paw.
Periodic vessel contractions were evident in the raw fluorescence measurements, and signal troughs could be manually
counted to identify number of pulses per unit time. Due to
the noise in the data, relative intensities of pulses, to each
other and to the overall uptake, were not estimated. The number
of pulses per unit time was used to describe the “active propulsion.” The early time points where tracer is rapidly taken into the
lymph vessels were called the “transient” phase, and the later
time points where dye fluorescence steadily declines are the
“steady-state” phase as it can be used to estimate the resting contractile lymphatic propulsion. For MB, the transient phase lasted
between ∼0 and 2 min, and for IgG-IRDye, it was ∼0 to 15 min.
Figure 3 shows a representative set of overall uptake curves
for MB and mouse IgG-IRDye in the axillary node and a corresponding afferent lymph vessel segment at a location ∼5 mm
to the node. The curves were normalized to the peak fluorescence signal in the vessel. IgG accumulation peaks at ∼60 min
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Fig. 2 Active and passive components of lymphatic uptake of MB.
Inset shows representative ROI locations (circles were enlarged to
be visible, actual ROI size was ∼2 mm for nodes and 0.5 mm for
lymph vessels). ROI circles are color coded to match the uptake
curves. Raw data (light solid lines) and smoothed curves (dotted
lines) are shown. 5-mm scale bar is shown on inset.

Normalized fluorescence (A.U)

in the lymph node and MB peaks at ∼1 min. The peak fluorescence is attained in the vessel segment much earlier than in the
node. The MB vessel peak, is missed in these presented data
from one animal, owing to the fact that it can get taken up during
injection itself and is instantaneously driven forward. MB is not
retained within the lymph node and clears immediately, whereas
IgG, owing to its large size, remains in the lymph node for a
significantly longer time.
The time to reach the peak fluorescence in the node, T peak;N
was noted for all animals and found to be 0.8  0.4 min
(median  standard deviation, excluding outliers beyond
2σ), in the MB group, and 65  23 min in the IgG-IRDye
group. Similarly, time to peak in the vessel T peak;V was observed
to be 0.6  0.2 min and 8  6 min in the MB and IgG-IRDye
groups, respectively [see Figs. 4(a) and 4(b)]. The differences
between these groups were found to be significant with
p value ≈ 0 for nodes and p value ¼ 0.008 in the vessels.
We have previously shown that raw intensity measurements
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Fig. 3 Comparison of passive uptake components of MB and IgGIRDye shown in a representative lymph node (solid) and its corresponding afferent lymph vessel (dotted). MB clears rapidly from the
node owing to its small size. Inset shows a time-expanded view.
Note that curves were smoothed, so active lymph vessel propulsion
is not evident here. The second peak (indicated by red asterisk in the
main plot) of the double peak seen in the IgG-IRDye uptake in the
lymph node was always found to be higher in signal intensity that
the first and was chosen for peak time and intensity estimation.
Color-coded asterisks have been used to indicate peak locations.
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on the nodes are highly unreliable and prone to high-signal
heterogeneity, attributable to heterogeneity in delivery by the
lymphatic vessel,16 and so vessel signal-based normalization
improves the quantification of signal in the nodes provided
that a single vessel delivers tracer, and tracer has not entered
the blood stream. We report vessel-peak normalized node fluorescence N∕V in Fig. 4(c) and found that this ratio was 1.7  0.8
in the MB group and 7  4 in the IgG-IRDye group, revealing
a statistically significant difference between groups with
p value ¼ 0.004. All the above parameters are related to the
slower rate of uptake of IgG-IRDye as compared to the
much smaller MB molecule at the lymphatic–interstitial interface. If this flow was purely diffusive their relative transport
times would be dominated by the Stokes–Einstein diffusion
coefficient D, (D ¼ kT∕6πηr) (where k is the Bolztmann constant, T is the temperature, η is the viscocity, and r is the particle
radius). Given the relative sizes, r ∼ ðMWÞ1∕3 , of the MB to
IgG, their relative diffusion coefficients would be a ratio of
1:7.9. This ratio is interstingly very close to the measured
ratio of time to peak [see Fig. 4(b)], 0.6:8, in the afferent vessels,
and within the error bounds of the estimates, indicating that diffusive transport dominates this slower passive uptake process,
although the ratio in the nodes appears further from this, at
0.8:65, likely due to differing kinetics of tracer exiting the
nodes to downstream lymphatics and vasculature, a discussion
of which is beyond the scope of this work. The above indicates
that as long as the injected agent volume is constant and hence
interstitial pressure is constant, diffusion dominates the uptake
of molecules into the lymphatic capillaries.
The lymph nodes, being clearance organs, retain large proteins and molecules, and hence, the tracer lymphatic kinetics is
influenced by this retention. MB appears to be barely retained
by the node and is seen in the urine within minutes after injection (data not shown). Other studies suggest that MB has very
poor affinity for any plasma proteins due to the lack of sulphonic
acid groups,21 and hence mostly exists as free unassociated dye
that can travel swiftly into and out of the node. IgG-IRDye on
the other hand is likely trapped in the lymph node sinuses and
clears slowly after injection.
Figures 4(d) and 4(e) show the intensity independent“active” propulsive components of the transport. Contractions
of smooth muscles lining the walls of the collector lymph vessels drive the lymph packets from one lymphangion to the next.
The number of complete pulses per minute was counted from
the raw fluorescence data as shown in Fig. 2. The early time
points during which tracer signal in the node and lymph vessel
were rapidly changing (∼0 to 2 min for MB and ∼0 to 15 min for
IgG) was labeled “Transient pump rate, ptrans” and the pump rate
over late time points was assumed to be indicative of the resting
pump rate and was labeled, “steady-state pump rate, p∞ .” We
estimated the time windows based upon the T peak;V median values, which were 0.6 and 8 min for MB and IgG, respectively. We
approximated that “steady state” time would exist after about
twice this duration across all animals, and that the uptake
from the 0-min time point to the 2 × T peak;V time point would
be “transient state.” For the MB and IgG cohorts, transient pump
rates were observed to be 6.1  1.3 and 4.2  1.2 pulses∕ min
(p value ¼ 0.15), and steady-state pump rates were 3.4  0.8
and 3.3  0.5 pulses∕ min (p value ¼ 0.34). The pump rates
were similar for the MB and IgG cohorts indicating that molecule size does not affect the propulsion rate due to lymphatic
vessel contractions. Aldrich et al.17 observed similar pumping
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Fig. 4 (a)–(e) Comparison of various measured parameters for MB
(N ¼ 8) and MIgG-IRDye 680RD (N ¼ 5) cohorts. (f) shows comparison bar graphs of transient versus steady-state propulsion rate in all
animals. * indicates significant difference with p value < 0.009.

(propulsion) rates in their comparison of indocyanine green,
IRDye 800CW, and an antibody, though they did not
separate transient and steady-state rates, and instead used the
average rate over 20 min. Given that there was no significant
differences in pump rates between the MB and IgG
cohorts, we pooled the results from both cohorts and compared
the transient (6.0  1.4 pulses∕ min) and steady-state rate
(3.4  0.8 pulses∕ min) within each mouse using a pairedstudent’s t-test and found that the differences were significant
with p value ≈ 0, indicating that the collector lymphatics likely
do respond to luminal pressure changes in the initial lymphatic
capillaries.23 While we expect that there are differences in the
intersitital oncotic pressure due to IgG versus MB, the hydrostatic pressure is likely dominant (due to large injection volume
of 10 μl) preventing differences between MB and IgG to be significant in influencing interstitial pressure. Also, note that no
detectable contraction was observed in the lymph nodes.
The study of the lymphatic physiology has largely been limited by the inability to image the lymphatic architecture in real
time at a sampling rate greater than the lymphatic smooth
muscle contraction rate. Recent attempts using near-infrared and
far-red fluorophores, and imaging using microscopy methods,
such as intravital microscopy9 and broad-beam NIRF imaging,10
have lead the way in quantitative imaging of lymphatic vessels
but so far do not describe the relationship between tracer size
and various components of transport. Through this work we
quantitatively studied and compared active propulsion and passive uptake in the lymphatics for large and small tracers and
hope to elucidate the importance of identifying these components of transport; we expect that this work will be one piece
in the puzzle of developing the right tools to study the lymphatic
vasculature and use appropriate physiological models, which
will in turn impact the ability to better diagnose lymphatic diseases, such as metastasis, noninvasively.
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